Medication safetyLast medically sourced: 21 July 2026

Mounjaro® KwikPen®: Important safety information

Read this information before starting Mounjaro and keep the patient leaflet supplied with your medicine. This page does not replace advice from your doctor, pharmacist, or nurse.

Mounjaro is a prescription-only medicine. It is not suitable for everyone. Completing a DarDoc assessment does not guarantee a prescription.

Do not use Mounjaro if

You are allergic to tirzepatide or any other ingredient in Mounjaro.

Do not share your pen or prescription with another person. Do not combine Mounjaro with another tirzepatide medicine or another GLP-1 medicine unless your prescriber directs you to.

Tell your clinician before using Mounjaro

Tell your doctor, pharmacist, or nurse about every health condition and all prescription medicines, over-the-counter medicines, vitamins, and supplements you use. In particular, tell them if you:

Have severe digestive problems, including severe delayed stomach emptying, or gastroparesis.

Have or have previously had pancreatitis.

Have diabetic retinopathy, diabetic macular oedema, or another diabetes-related eye problem.

Have kidney problems or are at increased risk of dehydration.

Take insulin or a sulfonylurea. The combination can increase the risk of low blood sugar.

Take an oral medicine that requires careful or rapid absorption, including warfarin or digoxin. Mounjaro delays stomach emptying and may affect the timing of absorption.

Use an oral contraceptive and have obesity or overweight.

Are 85 years of age or older; clinical experience in this age group is very limited.

Are pregnant, think you may be pregnant, are planning pregnancy, or are breastfeeding.

Are planning surgery or another procedure involving general anaesthesia or deep sedation. Delayed stomach emptying may increase the risk of stomach contents entering the lungs.

Pregnancy, contraception, and breastfeeding

Mounjaro should not be used during pregnancy. Use contraception while receiving treatment. If you plan to become pregnant, speak with your clinician about stopping Mounjaro at least one month beforehand. If you become pregnant while using Mounjaro, contact your clinician promptly.

If you have obesity or overweight and use an oral contraceptive, consider switching to a non-oral method or adding a barrier method, such as a condom, for four weeks after starting Mounjaro and for four weeks after every dose increase.

Only use Mounjaro while breastfeeding after discussing it with your clinician. Tirzepatide passes into breast milk in undetectable to very low amounts after a single studied dose, but the effect of reduced maternal food intake on breast-milk composition is not known.

Stop using Mounjaro and seek urgent medical help if you experience

Possible pancreatitis

Severe, persistent pain in the stomach area, which may move to the back, with or without nausea or vomiting. Acute pancreatitis can be serious and potentially life-threatening.

A severe allergic reaction

Difficulty breathing or swallowing; rapid swelling of the lips, tongue, face, or throat; or a fast heartbeat. Anaphylaxis and angioedema have been reported rarely.

Contact your clinician promptly if you experience

Ongoing vomiting or diarrhoea, difficulty drinking enough fluid, reduced urination, persistent dizziness, or other signs of dehydration.

New or worsening vision problems, especially if you have diabetic retinopathy or macular oedema.

Persistent or severe digestive symptoms or symptoms of delayed stomach emptying.

Persistent upper abdominal pain, fever, or yellowing of the skin or eyes, which may indicate gallstones or gallbladder inflammation.

A fast heartbeat, faintness, or persistent dizziness.

Any side effect that is severe, does not improve, or makes it difficult to eat, drink, or take other medicines.

Low blood sugar

Mounjaro can increase the risk of low blood sugar when used with insulin or a sulfonylurea. Your clinician may reduce the dose of those medicines and ask you to monitor your blood sugar.

Warning signs may include:

Headache

Drowsiness or weakness

Dizziness

Hunger

Confusion or irritability

Fast heartbeat

Sweating

Ask your clinician how to recognise and treat low blood sugar. Avoid driving or using machinery if symptoms affect your concentration.

Possible side effects

Like all medicines, Mounjaro can cause side effects, although not everybody gets them. Side-effect frequency can differ according to whether Mounjaro is used for type 2 diabetes or weight management and which other medicines are used.

Very common

These may affect more than 1 in 10 people:

Nausea

Diarrhoea

Vomiting

Stomach pain

Constipation

Low blood sugar when used for type 2 diabetes with insulin or a sulfonylurea

Nausea, vomiting, and diarrhoea occur most often while the dose is being increased and usually decrease over time. They should not be described as proof that treatment is working. Vomiting and diarrhoea may cause dehydration and worsen kidney function.

Common

These may affect up to 1 in 10 people:

Mild allergic reactions, such as rash, itching, or eczema

Dizziness or low blood pressure during weight-management treatment

Indigestion

Bloating

Burping

Gas

Reflux or heartburn

Hair loss during weight-management treatment

Tiredness

Injection-site reactions, such as redness or itching

Increased lipase on a blood test

Increased calcitonin on a blood test

Gallstones

Uncommon

These may affect up to 1 in 100 people:

Acute pancreatitis

Gallbladder inflammation during weight-management treatment

Injection-site pain

Changed sense of taste

Changes in skin sensation

Delayed stomach emptying

Fast pulse during weight-management treatment

Increased amylase on a blood test during weight-management treatment

Rare

These may affect up to 1 in 1,000 people:

Severe allergic reactions, including anaphylaxis and angioedema

Read the leaflet supplied with your medicine for the complete current list.

How to use Mounjaro safely

Use Mounjaro exactly as prescribed. Do not change your dose yourself.

The usual starting dose is 2.5 mg once weekly for four weeks, followed by 5 mg once weekly.

If needed, the prescriber may increase the dose in 2.5 mg steps after at least four weeks at the current dose, up to 15 mg once weekly.

Inject under the skin of the stomach area, upper leg, or back of the upper arm.

Use it at any time of day, with or without meals, preferably on the same day each week.

Rotate injection sites. If you also inject insulin, use a different injection site for it.

Read the instructions supplied with the KwikPen and have a clinician or pharmacist show you how to use it before the first dose.

Each KwikPen contains four 0.6 mL doses. Do not attempt to use liquid left after the four labelled doses.

Never share the pen or needles.

If you miss a dose

If four days or less have passed, take the missed dose as soon as you remember, then take the next dose on the usual day.

If more than four days have passed, skip the missed dose and take the next dose on the usual day.

Do not take a double dose. Leave at least three days between doses.

The weekly dosing day may be changed if at least three days have passed since the previous dose.

If you use more than prescribed

Contact your doctor immediately. Too much Mounjaro may cause nausea, vomiting, or low blood sugar and may require observation and supportive treatment. There is no specific antidote.

Storage and disposal

Keep Mounjaro out of the sight and reach of children.

Store it in a refrigerator at 2°C to 8°C.

Do not freeze it. Do not use a pen that has been frozen.

After first use, the pen may be stored outside the refrigerator below 30°C for up to 30 days. Discard it after that period.

Do not use the pen after its expiry date, if it is damaged, or if the medicine is cloudy, discoloured, or contains particles.

Ask your pharmacist how to dispose of used needles, used pens, and unused medicine. Do not dispose of medicines in wastewater or household waste.

Report a suspected side effect in the UAE

Tell your doctor or pharmacist about any suspected side effect.

Lilly UAE pharmacovigilance: pv-mea@lilly.com · +971 55 432 5014

Emirates Drug Establishment: pv@ede.gov.ae · EDRUG call centre 800 33784

Seek emergency care first for severe or life-threatening symptoms.

Sources

Last medically sourced: 21 July 2026.

UAE registration, prescription status, strengths, form, and pack presentation were checked against the EDE registered medical product directory, including the Mounjaro 2.5 mg KwikPen record.

Detailed indication and safety wording was cross-checked against Lilly's current April 2026 Mounjaro KwikPen patient leaflet and Summary of Product Characteristics, plus the EMA Mounjaro product-information record. Lilly's Gulf product-information portal identifies Mounjaro for UAE users but restricts the local document to prescribed patients and healthcare professionals.

The U.S.-specific boxed thyroid warning is not included because it is not present in the Lilly UK/EU information used for this page.